RBC Capital raises Neurocrine Biosciences price target

Created at 4 Jun · 08:29 UTC4 sources↑ Market-relevant4 events

IN SHORT

RBC Capital has increased its price target on Neurocrine Biosciences (NBIX), citing a revised outlook on the company's stock performance.

Who's Involved

RBC Capital

Analyst firm raising Neurocrine Biosciences price target

Neurocrine Biosciences

Company whose stock price target was raised

Key facts

RBC Capital raised its price target on Neurocrine Biosciences.
The adjustment reflects a revised outlook on the company's stock performance.

RBC Capital has raised its price target on Neurocrine Biosciences (NBIX). This adjustment reflects a revised outlook on the company's stock performance.

↳ Why This Matters

Analyst price target changes can influence investor sentiment and stock valuation.

FREQUENTLY ASKED

Neurocrine Biosciences (NBIX) had its price target raised.

RBC Capital raised the price target.

The adjustment reflects a revised outlook on the company's stock performance.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

CME Headlines

RBC Capital raises Neurocrine Biosciences price target

PiQ Daily

Key facts

Get the newsletter.

RBC Capital raises Neurocrine Biosciences price target

PiQ Daily

Key facts

Get the newsletter.